ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Enliven Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$38.70+1.38 (+3.70%)
Close on Oct 19, 2026
- Market cap
- $2.56B
- P/E (TTM)
- –
- Dividend yield
- –
Enliven Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Market Cap | $2.84B | $166.30M |
| Enterprise Value | $1.94B | $88.19M |
| PB Ratio | 3.17 | 2.03 |
| P/TBV Ratio | 3.17 | 2.29 |
Income (trailing twelve months)
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$124.41M | -$21.40M |
| Net Income | -$105.93M | -$22.46M |
| EBITDA | -$124.25M | -$16.91M |
| EPS (Diluted) | -$1.67 | -$0.83 |
Returns
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -15.3% | -53.2% |
| Return on Assets (ROA) | -15.0% | -40.9% |
| Return on Capital Employed (ROCE) | -13.9% | -38.1% |
Balance sheet
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $895.20M | $61.43M |
| Net Cash (Debt) | $895.20M | $15.35M |
| Net Cash Per Share | $12.22 | $0.66 |
| Equity (Book Value) | $895.15M | $49.09M |
| Book Value Per Share | $12.22 | $1.37 |
| Tangible Book Value | $895.15M | $23.52M |
| Working Capital | $893.18M | $76.81M |
Financial position
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 64.07 | 3.34 |
| Quick Ratio | 63.22 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$66.94M | -$12.35M |
| Capital Expenditures | -$98.00K | -$1.08M |
| Free Cash Flow | -$67.04M | -$20.22M |
| FCF Per Share | -$0.91 | -$0.42 |
Efficiency
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.77M | -$703.34K |
| Employee Count | 60 | 74 |
Dividends and yields
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -3.74% | -23.3% |
| FCF Yield | -2.36% | -8.72% |
Shares
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 73,270,800 | 58,127,000 |
| Shares Change (YoY) | 26.5% | 10.9% |
| Shares Change (QoQ) | 20.3% | 0.54% |
| Float | 56,494,400 | 49,136,700 |
| Shares Held by Insiders | 22.9% | 11.6% |
| Shares Held by Institutions | 109.8% | 59.4% |
Scores
| Measure | Enliven Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 112.97 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Enliven Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.